Development of a model of focal pneumococcal pneumonia in young rats
Richard Malley1, Anne M Stack, Robert N Husson
1Division of Emergency Medicine, Children's Hospital, Harvard Medical School, Boston MA, USA. richard.malley@childrens.harvard.edu
Insights
Researchers developed a rat model for Streptococcus pneumoniae pneumonia. This model reliably produced pneumonia and mortality, aiding vaccine evaluation for preventing pneumococcal pneumonia.
Area of Science:
- Infectious Disease
- Pulmonology
- Vaccinology
Background:
- Pneumococcal conjugate vaccines are effective against bacteremia but their impact on pneumonia is unclear.
- Evaluating vaccine efficacy against pneumococcal pneumonia requires a suitable animal model.
- Streptococcus pneumoniae is a leading cause of bacterial pneumonia worldwide.
Purpose of the Study:
- To develop and validate an animal model for Streptococcus pneumoniae pneumonia.
- To assess the utility of this model for evaluating preventative strategies against pneumococcal pneumonia.
Main Methods:
- Establishment of a rat model using intrapulmonary instillation of Streptococcus pneumoniae serotypes 3 and 6B in Sprague-Dawley pups.
- Assessment of outcomes including pneumonia development, bacteremia, mortality, and lung histology.
- Evaluation of prophylactic anticapsular antibody efficacy in preventing disease.
Main Results:
- Reliable induction of pneumonia and mortality with Streptococcus pneumoniae serotypes 3 and 6B, dose-dependent effects observed.
- Increased mortality correlated with higher bacterial inoculums for both serotypes.
- Prophylactic administration of anticapsular antibodies successfully prevented type 3 pneumococcal pneumonia and associated mortality.
Conclusions:
- The developed rat model effectively replicates key features of Streptococcus pneumoniae pneumonia.
- This model is proposed as a valuable tool for preclinical evaluation of vaccines targeting pneumococcal pneumonia.
- Further research using this model can inform the development of more effective pneumococcal vaccines.
Abstract:
BACKGROUND: A recently licensed pneumococcal conjugate vaccine has been shown to be highly effective in the prevention of bacteremia in immunized children but the degree of protection against pneumonia has been difficult to determine. METHODS: We sought to develop a model of Streptococcus pneumoniae pneumonia in Sprague-Dawley rats. We challenged three-week old Sprague-Dawley pups via intrapulmonary injection of S. pneumoniae serotypes 3 and 6B. Outcomes included bacteremia, mortality as well histologic sections of the lungs. RESULTS: Pneumonia was reliably produced in animals receiving either 10 or 100 cfu of type 3 pneumococci, with 30% and 50% mortality respectively. Similarly, with type 6B, the likelihood of pneumonia increased with the inoculum, as did the mortality rate. Prophylactic administration of a preparation of high-titered anticapsular antibody prevented the development of type 3 pneumonia and death. CONCLUSION: We propose that this model may be useful for the evaluation of vaccines for the prevention of pneumococcal pneumonia.
